Katharina Elisabeth Blankart
Names
first: |
Katharina |
middle: |
Elisabeth |
last: |
Blankart |
Identifer
Contact
Affiliations
-
Berner Fachhochschule
/ Department Gesundheit
/ Institut für Gesundheitsökonomie und Gesundheitspolitik (weight: 95%)
-
Universität Duisburg-Essen
/ Fachbereich Wirtschaftswissenschaften
/ Deutsches Forschungszentrum für Gesundheitsökonomik (CINCH) (weight: 5%)
Research profile
author of:
- A Hard Look at “Soft” Cost‐control Measures in Healthcare Organizations: Evidence from Preferred Drug Policies in Germany (RePEc:ajt:wcinch:74978)
by Avdic, Daniel & Blankart, Katharina - Policy as a strategy to innovate in health care? A content analysis of innovation policies in Germany, 1994–2017 (RePEc:bla:ijhplm:v:38:y:2023:i:6:p:1657-1675)
by Melina Sophie Kurte & Katharina Elisabeth Blankart - A structured tool to analyse coverage decisions: Development and feasibility test in the field of cancer screening and prevention (RePEc:eee:hepoli:v:101:y:2011:i:3:p:290-299)
by Fischer, Katharina E. & Leidl, Reiner & Rogowski, Wolf H. - A systematic review of coverage decision-making on health technologies—Evidence from the real world (RePEc:eee:hepoli:v:107:y:2012:i:2:p:218-230)
by Fischer, Katharina Elisabeth - Transparency vs. closed-door policy: Do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis (RePEc:eee:hepoli:v:112:y:2013:i:3:p:187-196)
by Fischer, Katharina E. & Rogowski, Wolf H. & Leidl, Reiner & Stollenwerk, Björn - Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia (RePEc:eee:hepoli:v:120:y:2016:i:10:p:1115-1122)
by Fischer, Katharina Elisabeth & Heisser, Thomas & Stargardt, Tom - Drug safety and the impact of drug warnings: An interrupted time series analysis of diabetes drug prescriptions in Germany and Denmark (RePEc:eee:hepoli:v:120:y:2016:i:12:p:1404-1411)
by Hostenkamp, Gisela & Fischer, Katharina Elisabeth & Borch-Johnsen, Knut - Dispensing behaviour of pharmacies in prescription drug markets (RePEc:eee:hepoli:v:120:y:2016:i:2:p:190-197)
by Guhl, Dennis & Stargardt, Tom & Schneider, Udo & Fischer, Katharina E. - The challenges of regulatory pluralism (RePEc:eee:hepoli:v:149:y:2024:i:c:s016885102400174x)
by Gillner, Sandra & Blankart, Katharina Elisabeth & Bourgeois, Florence Tanya & Stern, Ariel Dora & Blankart, Carl Rudolf - Funding Decisions for Newborn Screening: A Comparative Review of 22 Decision Processes in Europe (RePEc:gam:jijerp:v:11:y:2014:i:5:p:5403-5430:d:36212)
by Katharina Elisabeth Fischer & Wolf Henning Rogowski - Physician-Level Cost Control Measures and Regional Variation of Biosimilar Utilization in Germany (RePEc:gam:jijerp:v:17:y:2020:i:11:p:4113-:d:369171)
by Katharina E. Blankart & Friederike Arndt - Are patients more adherent to newer drugs? (RePEc:kap:hcarem:v:23:y:2020:i:4:d:10.1007_s10729-020-09513-5)
by Katharina E. Blankart & Frank R. Lichtenberg - A hard look at soft cost-control measures in healthcare organizations: Evidence from preferred drug policies in Germany (RePEc:mhe:chemon:2021-07)
by Daniel Avdic & Katharina E. Blankart - The Effects of Off-label Drug Use on Disability and Medical Expenditure (RePEc:nbr:nberwo:30440)
by Katharina E. Blankart & Frank R. Lichtenberg - Improving Service Provision - The Health Care Services' Perspective (RePEc:nms:nomsmr:10.15358/2511-8676-2019-4-163)
by Winter, Vera & Thomsen, Mette Kjærgaard & Schreyögg, Jonas & Blankart, Katharina & Duminy, Lize & Schoenenberger, Lukas & Ansah, John P. & Matchar, David & Blankart, Carl Rudolf & Oppel, Eva & Jensen, - Link between Process and Appraisal in Coverage Decisions (RePEc:sae:medema:v:33:y:2013:i:8:p:1009-1025)
by Katharina E. Fischer & Björn Stollenwerk & Wolf H. Rogowski - Early Benefit Assessment of Pharmaceuticals in Germany (RePEc:sae:medema:v:34:y:2014:i:8:p:1030-1047)
by Katharina E. Fischer & Tom Stargardt - Analysing coverage decision-making: opening Pandora’s box? (RePEc:spr:eujhec:v:15:y:2014:i:9:p:899-906)
by Katharina Fischer & Reiner Leidl - The diffusion of generics after patent expiry in Germany (RePEc:spr:eujhec:v:17:y:2016:i:8:d:10.1007_s10198-015-0744-3)
by Katharina Elisabeth Fischer & Tom Stargardt - The impact of physician-level drug budgets on prescribing behavior (RePEc:spr:eujhec:v:19:y:2018:i:2:d:10.1007_s10198-017-0875-9)
by Katharina Elisabeth Fischer & Taika Koch & Karel Kostev & Tom Stargardt - Insurance barriers and inequalities in health care access: evidence from dual practice (RePEc:spr:hecrev:v:14:y:2024:i:1:d:10.1186_s13561-024-00500-y)
by Eva Goetjes & Katharina E. Blankart - To Seek Program Accreditation, Innovation, or Both?—Examining the Interdependencies in High-Reliability Health Care Organizations (RePEc:spr:sjobre:v:75:y:2023:i:3:d:10.1007_s41471-023-00168-w)
by Tim Brand & Eva Goetjes & Katharina Blankart - Arzneimittel: Placebo bei Engpassbekämpfung
[Pharmaceuticals: Placebo in combating bottlenecks] (RePEc:spr:wirtsc:v:102:y:2022:i:4:d:10.1007_s10273-022-3148-x)
by Katharina Blankart & Stefan Felder - Regional Innovation Systems of Medical Technology: A knowledge production function of cardiovascular research and funding in Europe (RePEc:wiw:wiwreg:region_8_2_352)
by Rucha Vadia & Katharina Blankart - The impact of drug quality ratings from health technology assessments on the adoption of new drugs by physicians in Germany (RePEc:wly:hlthec:v:29:y:2020:i:s1:p:63-82)
by Katharina Elisabeth Blankart & Tom Stargardt - The effects of off-label drug use on disability and medical expenditure (RePEc:zbw:rwirep:969)
by Blankart, Katharina & Lichtenberg, Frank R.